Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
2.52(c) 2.625(c) 2.65(c) 2.65(c) 2.635 Last
51 396 245 508 107 114 213 642 38 881 Volume
+0.20% +4.17% +0.95% 0.00% -0.57% Change
More quotes
Estimated financial data (e)
Sales 2021 10,2 M 11,5 M 11,5 M
Net income 2021 -29,8 M -33,7 M -33,7 M
Net cash position 2021 3,35 M 3,80 M 3,80 M
P/E ratio 2021 -7,91x
Yield 2021 -
Sales 2022 8,65 M 9,81 M 9,81 M
Net income 2022 -35,1 M -39,8 M -39,8 M
Net Debt 2022 36,7 M 41,6 M 41,6 M
P/E ratio 2022 -6,79x
Yield 2022 -
Capitalization 259 M 293 M 293 M
EV / Sales 2021 25,1x
EV / Sales 2022 34,1x
Nbr of Employees 133
Free-Float 44,0%
More Financials
Company
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The... 
Read more
More about the company
Ratings of Transgene
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about TRANSGENE
01/20Transgene-BioInvent's Solid Tumor Drug Shows Potential Benefits in Preclinical Studies
MT
01/18Transgene and PersonGen Biotherapeutics Announce Collaboration to Evaluate New Combinat..
CI
2021AstraZeneca Exercises Option for License to Oncolytic Virus Based on Transgene's Invir...
MT
2021AstraZeneca Licenses Oncolytic Virus in Option Exercise Under Transgene Deal
MT
2021Transgene Announces License Option Exercise by Astrazeneca for an Oncolytic Virus Gener..
CI
2021Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies o..
CI
2021Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral A..
CI
2021TRANSGENE : 3rd quarter earnings
CO
2021BIOINVENT INTERNATIONAL : and Transgene to present preclinical data on BT-001 oncolytic vi..
AQ
2021Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2..
CI
2021Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 23..
CI
2021TRANSGENE : Half-year report
CO
2021TRANSGENE : Half-year results
CO
2021TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing Virus
MT
2021Transgene Presents Data from Phase I Clinical Trial Confirming the Potential of the Onc..
CI
More news
News in other languages on TRANSGENE
01/20TRANSGENE : parution d'un article dans une revue scientifique
01/20Le médicament contre les tumeurs solides de Transgene-BioInvent montre des avantages po..
01/20EN DIRECT DES MARCHES : Alstom, Virbac, Soitec, Valneva, Unilever, Google, Deliveroo, Zur ..
01/19Les valeurs à suivre aujourd'hui à la Bourse de Paris Mercredi 19 janvier 2022
01/19EN DIRECT DES MARCHES : Orange, Gecina, Eurazeo, ASML, Richemont, Sony, Ford, EQT, Burberr..
More news
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,65 €
Average target price 3,95 €
Spread / Average Target 49,1%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE4.33%293
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805